Smyth J F, Poplack D G, Holiman B J, Leventhal B G, Yarbro G
J Clin Invest. 1978 Sep;62(3):710-2. doi: 10.1172/JCI109179.
Adenosine deaminase (ADA) activity has been measured in the lymphoblasts of 23 untreated patients with acute lymphoblastic leukemia and related to the presence or absence of immunologic cell surface markers. The mean ADA activity in the acute lymphoblastic leukemia population as a whole was increased fourfold over that in normal lymphocytes. 9 of the 23 patients were classified as thymus-derived (T-) cell acute lymphoblastic leukemia on the basis of erythrocyte rosette positivity; the remaining 14 patients had null-cell leukemia. The mean ADA activity (ADA U/mg protein) of T-cell lymphoblasts (102 U) was 3 times higher than the mean of null lymphoblasts (30 U). This difference is statistically significant (P less than 0.02). Measurement of ADA activity offers a biochemical method of distinguishing between immunological subtypes of lymphoblasts which may be of prognostic and therapeutic value.
已对23例未经治疗的急性淋巴细胞白血病患者的淋巴母细胞中的腺苷脱氨酶（ADA）活性进行了测定，并将其与免疫细胞表面标志物的有无相关联。急性淋巴细胞白血病总体人群中的ADA平均活性比正常淋巴细胞中的升高了四倍。23例患者中有9例根据红细胞玫瑰花结阳性被归类为胸腺来源（T-）细胞急性淋巴细胞白血病；其余14例患者患有无标记细胞白血病。T细胞淋巴母细胞的平均ADA活性（ADA U/毫克蛋白质）为102 U，比无标记淋巴母细胞的平均值（30 U）高3倍。这种差异具有统计学意义（P小于0.02）。ADA活性的测定提供了一种区分淋巴母细胞免疫亚型的生化方法，这可能具有预后和治疗价值。
